Cellectis SA (CLLS) has released an update.
Cellectis SA, a clinical-stage biotechnology company, has announced it will hold its annual general meeting on June 28, 2024, in Paris, France. Investors and other interested parties can access details regarding the meeting’s agenda and participation on the company’s website. Cellectis is recognized for its innovative gene-editing platform and its development of cell and gene therapies, including its proprietary TALEN technology and PulseAgile electroporation system.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
